TRPV1 Antagonists for Hot Flush Thermal Discomfort
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hot flushes, such as estrogen therapy, are not selective and come with dangerous side effects, while neurokinin-3 receptor antagonists were abandoned due to hepatotoxicity, highlighting a need for a safe and specific therapy targeting hot flushes.
Innovation Solution
The use of transient receptor potential channel (TRP channel) blockers, specifically TRPV1 antagonists like capsazepine, A1165442, and SB366791, administered topically or in various formulations, to treat hot flushes by targeting thermal discomfort.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If estrogen therapy is used to treat hot flushes, then thermal discomfort is reduced, but dangerous side effects occur and treatment lacks selectivity
Solution Approach 1:
The invention segments the treatment approach by targeting a specific receptor subtype (TRPV1) involved in thermal sensation, rather than using broad-acting estrogen therapy. This selective targeting isolates the therapeutic effect to thermal discomfort management while avoiding the systemic side effects of estrogen, thus resolving the contradiction between treatment effectiveness and safety.
Solution Approach 2:
The patent applies local quality by using TRPV1 antagonists that specifically block thermal sensation pathways in the nervous system. This localized action on thermal perception neurons provides relief from hot flushes without affecting other physiological systems, thereby eliminating the harmful side effects associated with systemic estrogen therapy.
2Object-affected harmful factors
If neurokinin-3 receptor antagonist is used to treat hot flushes, then treatment specificity is improved, but hepatotoxicity occurs
Solution Approach 1:
The invention introduces TRPV1 antagonists as an intermediary therapeutic agent that mediates relief from thermal discomfort through a different physiological pathway than neurokinin-3 receptors. This alternative mediator achieves treatment specificity for hot flushes while avoiding the hepatotoxicity associated with neurokinin-3 receptor blockade, thus resolving the contradiction between specificity and safety.
3Object-affected harmful factors
If TRP channel blockers are used to target thermal discomfort, then treatment selectivity is improved, but risk of hyperthermia exists
Solution Approach 1:
The patent applies parameter changes by carefully controlling the dosage and pharmacokinetic parameters of TRPV1 antagonists to achieve selective blockade of thermal sensation without causing systemic hyperthermia. By optimizing these parameters, the treatment maintains high selectivity for thermal discomfort relief while minimizing the risk of harmful hyperthermic effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
TRP channel blockers effectively reduce thermal discomfort associated with hot flushes, offering a potential solution that avoids the side effects of existing treatments, and can be administered in ways that minimize adverse effects like hyperthermia.
Implementation Method 1
treating hot flushes comprises: providing a composition comprising a transient receptor potential channel (TRP channel) blocker
Data Source
AI summary
Disclosed herein are methods for treating hot flushes in a subject. In one embodiment, treating hot flushes includes administering to a subject in need of such treatment, a therapeutically effective amount of a transient receptor potential channel (TRP channel) blocker or a pharmaceutically acceptable salt thereof. Also disclosed herein are methods for amelioration, alleviation, or prevention of the thermal discomfort in hot flushes, comprising: selecting a subject in need of treatment for hot flushes, administering to the subject a therapeutically effective amount of a TRP channel blocker, such as a TRPV1 blocker, or a pharmaceutically acceptable salt thereof.